Addiction & Substance Use

Adolescent cannabis use surges in Oklahoma, raising public health concerns amid rising THC potency and permissive regulations.

Jail diversion programs offer vital support for individuals with mental health and substance use disorders, promoting recovery and reducing recidivism.

Discover how combining transcranial magnetic stimulation and ketamine therapy revolutionizes treatment for complex conditions like depression and pain.

Nutriband engages with the FDA on its innovative abuse-deterrent fentanyl patch, paving the way for safer pain management solutions.

New research reveals how Candida albicans in the gut microbiome influences alcohol consumption and aversion, offering insights for treating alcohol use disorder.

In this CME article, explore the complexities of movement disorders in psychiatric practice, including their causes, symptoms, and treatment strategies for better patient care.

AI chatbots rapidly integrate into daily life, raising concerns about dependency and mental health risks, paralleling the dangers of drug addiction.

Cannabis use among older adults surges as they seek relief from pain and anxiety, prompting clinicians to navigate complex treatment challenges.

Cognition Therapeutics advances zervimesine phase 2 trial, exploring its potential to slow cognitive decline in Alzheimer disease patients.

Achieve Life Sciences gains FDA acceptance for cytisinicline, a promising new drug for smoking cessation, showing significant abstinence rates in trials.

Altimmune's pemvidutide gains FDA Fast Track designation for alcohol use disorder.

AI chatbots pose significant mental health risks, often exacerbating issues like suicide, self-harm, and delusions, highlighting urgent regulatory needs.

The FDA has granted a Type C Meeting to Nutriband for their Aversa fentanyl patch, which aims to revolutionize pain management with its innovative abuse-deterrent technology.

Adial Pharmaceuticals just wrapped a successful end of phase 2 meeting with the FDA and will now advance its innovative treatment for alcohol use disorder, AD04.

GLP-1 receptor agonists emerge as potential game-changers in psychiatric treatment, targeting mental disorders and improving cognitive function.

According to this pioneer, mental health professionals should embrace a new mindset: to consider how to can apply expertise not only within the confines of the exam room, but in boardrooms, in startups, in classrooms, and in community centers.

Brigitte Robertson, MD, shares information on innovative, genetically targeted treatments for alcohol use disorder, aiming to personalize care and improve patient outcomes.

Adial Pharmaceuticals advances its treatment for alcohol use disorder, AD04, with FDA meetings and promising genetic insights for targeted therapy.

A retired psychiatrist has a conversation with AI about substance use disorder treatment.

Female offenders in the criminal justice system are more likely to have experienced trauma and are more likely to be diagnosed with conditions such as PTSD and depression compared with male offenders.

The prevalence of tobacco use in schizophrenia is over 60%—3 times that of the general population. However, the reason for the high prevalence of tobacco use in schizophrenia remains largely unknown.

Given that individual differences exist regarding the effects of brain injury and gaps persist in the treatment continuum, challenges arise in treating individuals with acquired brain injury. Addressing these challenges can improve patient outcomes.

Through cinematherapy, Ted Perkins created a program centered on addiction in film that is now used in recovery centers and clinics across the US and Canada.

March 17 through March 23 is National Drug and Alcohol Facts Week 2025.

BLP-003, currently being evaluated for treatment-resistant depression and alcohol use disorder, today announced their global phase 2b clinical trial has completed patient enrollment.